
Amgen's Five Prime takeover delivers gastric cancer win
Four years after buying Five Prime for $1.9 billion, Amgen has promising phase 3 results with a drug for gastric cancer that was the focal point for the deal. The new data comes from the FORTITUDE-101 looking at bemarituzumab plus chemotherapy as a front- …